IL179874A0 - Antibodies against west nile virus and therapeutic and prophylactic uses thereof - Google Patents

Antibodies against west nile virus and therapeutic and prophylactic uses thereof

Info

Publication number
IL179874A0
IL179874A0 IL179874A IL17987406A IL179874A0 IL 179874 A0 IL179874 A0 IL 179874A0 IL 179874 A IL179874 A IL 179874A IL 17987406 A IL17987406 A IL 17987406A IL 179874 A0 IL179874 A0 IL 179874A0
Authority
IL
Israel
Prior art keywords
therapeutic
antibodies against
west nile
nile virus
prophylactic uses
Prior art date
Application number
IL179874A
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of IL179874A0 publication Critical patent/IL179874A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IL179874A 2004-06-21 2006-12-06 Antibodies against west nile virus and therapeutic and prophylactic uses thereof IL179874A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58181904P 2004-06-21 2004-06-21
PCT/US2005/022251 WO2005122741A2 (en) 2004-06-21 2005-06-21 Antibodies against west nile virus and therapeutic and prophylactic uses thereof

Publications (1)

Publication Number Publication Date
IL179874A0 true IL179874A0 (en) 2008-03-20

Family

ID=35510219

Family Applications (1)

Application Number Title Priority Date Filing Date
IL179874A IL179874A0 (en) 2004-06-21 2006-12-06 Antibodies against west nile virus and therapeutic and prophylactic uses thereof

Country Status (8)

Country Link
US (3) US7527973B2 (en)
EP (1) EP1778879A4 (en)
JP (1) JP2008504029A (en)
AU (1) AU2005254110B2 (en)
CA (1) CA2571404A1 (en)
IL (1) IL179874A0 (en)
MX (1) MXPA06014795A (en)
WO (1) WO2005122741A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229617B2 (en) * 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
CA2571404A1 (en) * 2004-06-21 2005-12-29 Washington University Antibodies against west nile virus and therapeutic and prophylactic uses thereof
MX2007002883A (en) * 2004-09-13 2007-06-15 Macrogenics Inc Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof.
US7498419B2 (en) * 2004-10-14 2009-03-03 Washington University Crystals and structure of domain III of West Nile Virus envelope protein in association with a Fab fragment of a neutralizing antibody
WO2006067122A2 (en) * 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US8877187B2 (en) * 2005-07-25 2014-11-04 Avianax, Llc Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
EP1915395A2 (en) * 2005-07-25 2008-04-30 Avianax, Inc. Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
KR101508390B1 (en) 2006-06-06 2015-04-08 크루셀 홀란드 비.브이. Human binding molecules having killing activity against staphylococci and uses thereof
JP2008058194A (en) * 2006-08-31 2008-03-13 Kobe Univ Discrimination method of westnile virus infection
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EA200970834A1 (en) * 2007-03-06 2010-04-30 Рибовакс Байотекнолоджиз С.А. ANTIBODIES TO THE VIRUS VIRUS
EP2173866A2 (en) * 2007-06-29 2010-04-14 Avianax, LLC Vaccine production for pathogenic bird viral diseases
EP2464657B1 (en) 2009-08-10 2015-04-01 MorphoSys AG Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2015113055A2 (en) 2014-01-27 2015-07-30 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ade) of infection
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11884718B2 (en) 2018-04-24 2024-01-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
CN116751289B (en) * 2023-08-03 2023-10-20 中国人民解放军军事科学院军事医学研究院 anti-West Nile virus neutralizing antibody for reducing ADE effect and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455304B1 (en) * 1994-07-01 2002-09-24 The Board Of Regents Of The University Of Oklahoma Hyaluronate synthase gene and uses thereof
WO2002072036A2 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
US20030148267A1 (en) * 2001-11-09 2003-08-07 Schmidt Emmett Vance Screening assay for hepatitis C virus antiviral agents
US7351547B2 (en) * 2002-10-31 2008-04-01 Health Research, Inc. Diagnostic test for West Nile virus
CA2571404A1 (en) 2004-06-21 2005-12-29 Washington University Antibodies against west nile virus and therapeutic and prophylactic uses thereof
US7498419B2 (en) * 2004-10-14 2009-03-03 Washington University Crystals and structure of domain III of West Nile Virus envelope protein in association with a Fab fragment of a neutralizing antibody

Also Published As

Publication number Publication date
CA2571404A1 (en) 2005-12-29
US20060067940A1 (en) 2006-03-30
WO2005122741A2 (en) 2005-12-29
EP1778879A4 (en) 2010-02-24
EP1778879A2 (en) 2007-05-02
JP2008504029A (en) 2008-02-14
WO2005122741A3 (en) 2006-09-08
US20090258011A1 (en) 2009-10-15
AU2005254110B2 (en) 2010-12-09
MXPA06014795A (en) 2007-03-26
US7527973B2 (en) 2009-05-05
AU2005254110A1 (en) 2005-12-29
US20120076758A1 (en) 2012-03-29
US7981422B2 (en) 2011-07-19

Similar Documents

Publication Publication Date Title
IL179874A0 (en) Antibodies against west nile virus and therapeutic and prophylactic uses thereof
IL181477A0 (en) Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
EP1804831A4 (en) Listeria-based and llo-based vaccines
IL181025A0 (en) Novel anti-igf-ir antibodies and uses thereof
IL182554A0 (en) Anti-addl antibodies and uses thereof
HK1091116A1 (en) Recombinant il-9 antibodies and uses thereof
IL183723A0 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
IL183458A0 (en) Anti-il-1r1 single domain antibodies and therapeutic uses
IL179476A0 (en) Antibodies against human interleukin-13 and uses therefor
IL182453A0 (en) Vaccines against japanese encephalitis virus and west nile virus
EP1824796A4 (en) Protein scaffolds and uses thereof
IL178356A0 (en) Dr5 antibodies and uses thereof
EP1781308A4 (en) Natural anti- virus and composition comprising thereof
ZA200608100B (en) IRTA-5 antibodies and their uses
IL179497A0 (en) Carboranylporphyrins and uses thereof
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
EP1838288A4 (en) Therapeutic materials and methods
IL180365A0 (en) Carboranylporphyrins and uses thereof
GB0417345D0 (en) Substituted organopolysiloxanes and uses thereof
EP1812055A4 (en) Chlamydia antigens and uses thereof
EP1703887A4 (en) Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof
GB0417344D0 (en) Substituted organopolysiloxanes and use thereof
EP1833989A4 (en) Virus preparations and methods
ZA200704033B (en) Vaccines against Japanese encephalitis virus and west nile virus
GB0317376D0 (en) Immunogenic protein and uses thereof